254 related articles for article (PubMed ID: 17534899)
1. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
[TBL] [Abstract][Full Text] [Related]
2. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
[TBL] [Abstract][Full Text] [Related]
3. Stage-specific expression of breast cancer-specific gene gamma-synuclein.
Wu K; Weng Z; Tao Q; Lin G; Wu X; Qian H; Zhang Y; Ding X; Jiang Y; Shi YE
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):920-5. PubMed ID: 14504205
[TBL] [Abstract][Full Text] [Related]
4. Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.
Wu K; Huang S; Zhu M; Lu Y; Chen J; Wang Y; Lin Q; Shen W; Zhang S; Zhu J; Shi YE; Weng Z
Med Oncol; 2013; 30(3):612. PubMed ID: 23696021
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients.
Min L; Zhang C; Ma R; Li X; Yuan H; Li Y; Chen R; Liu C; Guo J; Qu L; Shou C
BMC Cancer; 2016 Sep; 16(1):717. PubMed ID: 27595752
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.
Cirak Y; Furuncuoglu Y; Yapicier O; Alici S; Argon A
Int J Clin Exp Pathol; 2015; 8(5):5345-53. PubMed ID: 26191236
[TBL] [Abstract][Full Text] [Related]
7. Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Min L; Ma RL; Yuan H; Liu CY; Dong B; Zhang C; Zeng Y; Wang L; Guo JP; Qu LK; Shou CC
Asian Pac J Cancer Prev; 2015; 16(7):2819-26. PubMed ID: 25854368
[TBL] [Abstract][Full Text] [Related]
8. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.
Strohl A; Mori K; Akers S; Bshara W; Buttin B; Frederick PJ; Helenowski IB; Morrison CD; Odunsi K; Schink JC; Scholtens DM; Wei JJ; Kim JJ
J Ovarian Res; 2016 Nov; 9(1):75. PubMed ID: 27809878
[TBL] [Abstract][Full Text] [Related]
9. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
11. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.
Liu H; Liu W; Wu Y; Zhou Y; Xue R; Luo C; Wang L; Zhao W; Jiang JD; Liu J
Cancer Res; 2005 Sep; 65(17):7635-43. PubMed ID: 16140929
[TBL] [Abstract][Full Text] [Related]
12. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.
Zhao W; Liu H; Liu W; Wu Y; Chen W; Jiang B; Zhou Y; Xue R; Luo C; Wang L; Jiang JD; Liu J
Int J Oncol; 2006 May; 28(5):1081-8. PubMed ID: 16596223
[TBL] [Abstract][Full Text] [Related]
13. [The correlation of synuclein-γ and matrix metalloproteinase 9 in breast cancer].
Chen J; Huang S; Wu KJ; Wang YK; Jia YJ; Lu YS; Weng ZY
Zhonghua Wai Ke Za Zhi; 2013 Jul; 51(7):641-4. PubMed ID: 24256593
[TBL] [Abstract][Full Text] [Related]
14. Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients.
Liu C; Guo J; Qu L; Bing D; Meng L; Wu J; Shou C
Cancer Lett; 2008 Sep; 269(1):148-58. PubMed ID: 18586385
[TBL] [Abstract][Full Text] [Related]
15. Combined phenotype of 4 markers improves prognostic value of patients with colon cancer.
Liu C; Qu L; Dong B; Xing X; Ren T; Zeng Y; Jiang B; Meng L; Wu J; Shou C
Am J Med Sci; 2012 Apr; 343(4):295-302. PubMed ID: 22261620
[TBL] [Abstract][Full Text] [Related]
16. Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen.
Liu C; Dong B; Lu A; Qu L; Xing X; Meng L; Wu J; Eric Shi Y; Shou C
BMC Cancer; 2010 Jul; 10():359. PubMed ID: 20604972
[TBL] [Abstract][Full Text] [Related]
17. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
[TBL] [Abstract][Full Text] [Related]
18. Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry.
Zhao J; Xing N
Med Sci Monit; 2014 Dec; 20():2550-5. PubMed ID: 25479371
[TBL] [Abstract][Full Text] [Related]
19. Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells.
Inaba S; Li C; Shi YE; Song DQ; Jiang JD; Liu J
Breast Cancer Res Treat; 2005 Nov; 94(1):25-35. PubMed ID: 16142440
[TBL] [Abstract][Full Text] [Related]
20. [SNCG expression and clinical significance in colorectal cancer liver metastasis].
Guo CG; Sun LC; Liu Q; Xie YB; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Jun; 15(6):625-8. PubMed ID: 22736138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
